ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements
Ajooni Biotech Ltd reported revenue from operations of ₹63.5 Cr (+102.9% YoY) and net profit of ₹0.4 Cr (-50.0% YoY) for Q1 FY27.
Ajooni Biotech has allotted 90 lakh equity shares to Healthy Biosciences Limited. The total issue value is ₹3.87 Crore.
Ajooni Biotech Limited has scheduled a board meeting for August 14, 2026. The board will consider and approve unaudited standalone financial results for the June 2026 quarter.
The company's shareholders approved an increase in its authorized share capital to ₹70 Crore at the 16th Annual General Meeting.
Ajooni Biotech received shareholder approval for the preferential issuance of 90,00,000 equity shares at Rs. 4.30 each, valued at approximately ₹3.87 Crore.
Ajooni Biotech shareholders approved the re-appointment of Mr. Gursimran Singh as Director at the 16th Annual General Meeting held on July 29, 2026.
Ajooni Biotech Limited held its 16th Annual General Meeting on July 29, 2026. The meeting covered financial statements, director re-appointment, and special business items.
AJOONI Biotech’s AGM on July 29, 2026 will vote on a Rs 20 crore capital uplift and a Rs 3.87 crore preferential issue to its promoter. Capital rises to Rs 70 crore.
Ajooni Biotech announced book closure from July 23 to 29, 2026. This is for its 16th Annual General Meeting on July 17, 2026.
Ajooni Biotech approved increasing its authorised share capital to Rs 70 crore. The change awaits shareholder approval at the July 29 AGM.
Ajooni Biotech’s board approved a preferential issue of up to 90 lakh shares raising Rs 3.87 crore. The meeting also increased authorized capital to Rs 70 crore and set the AGM for July 29, 2026.
Ajooni Biotech Ltd reported revenue from operations of ₹60.6 Cr (+106.8% YoY) and net profit of ₹0.9 Cr (-40.0% YoY) for Q4 FY26.
Ajooni Biotech Limited reported annual total income of ₹184.80 Crore for FY2026. The results show significant revenue growth compared to the previous year.
Ajooni Biotech Limited's board approved appointing M/s. N. Kumar & Company as internal auditors for F.Y. 2025-26. The move ensures continued regulatory compliance and internal governance.
Ajooni Biotech appointed M/s. N. Kumar & Company as Internal Auditors for financial year 2025-26. The appointment ensures continued regulatory compliance and internal control oversight.
Ajooni Biotech Limited has issued an undertaking to the National Stock Exchange confirming that its website (www.ajoonibiotech.com) is updated and fully functional. This filing is in compliance with Regulation 46 of the SEBI (LODR) Regulations, 2015, ensuring transparent information access for investors and regulators.
Ajooni Biotech Ltd reported net profit of ₹1.6 Cr (+128.6% YoY) for Q3 FY26.